Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy

Vaccines, Год журнала: 2023, Номер 11(5), С. 968 - 968

Опубликована: Май 10, 2023

For SARS-CoV-2 mutants, the effectiveness of COVID-19 vaccines is still controversial. In this study, we aimed to investigate clinical characteristics Omicron-infected patients who completed primary immunization and booster immunization, respectively, during rapid propagation Omicron variant in China. A total 932 with confirmed infection from 18 December 2022 1 January 2023 were included survey by filling out questionnaires online. The enrolled divided into group according their vaccination status. During whole course disease, most frequent symptoms fever (90.6%), cough (84.3%), weakness (77.4%), headache dizziness (76.1%), myalgia (73.9%). Nearly 90% had lasting for less than 10 days, 39.8% ended disease 4-6 days. 58.8% these a maximum body temperature over 38.5 °C. Moreover, 61.4% that lasted 2 There no obvious differences initial symptoms, cardinal symptom duration time, temperature, time between two groups patients. addition, significant difference was found positive or negative conversion antigen/nucleic acid mild breakthrough infection, enhanced has impact on performance viral compared immunization. reasons behind different manifestations after strain are worth further research. Heterologous may be better strategy which can help improve immune protection ability population. Further research should carried against mutant strains spectral anti-COVID-19 vaccines.

Язык: Английский

Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(19), С. 14965 - 14965

Опубликована: Окт. 6, 2023

SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants concern (VOC). We established new variant-adapted surrogate virus neutralization test (sVNT) and assessed activity ancestral B.1 (WT) VOC Delta, Omicron BA.1, BA.2, BA.5. Analytical performances were compared respective to reference (VNT) two CE-IVD labeled kits using three cohorts collected during COVID-19 waves. Correlation analyses showed moderate strong correlation for sub-variants (Spearman's r = 0.7081 0.7205 0.6042 BA.5), WT (r 0.8458) Delta-sVNT 0.8158), respectively. Comparison WT-sVNT performance with kits, "Icosagen Neutralizing Antibody ELISA kit" "Genscript cPass, revealed an overall good ranging from 0.8673 -0.8773 midway profile between both commercial 87.76% sensitivity 90.48% clinical specificity. The BA.2-sVNT was similar BA.2 Genscript test. Finally, analysis association 0.8583) BA.5-sVNT VNT sVNT double-vaccinated cohort (n 100) Omicron-breakthrough 91). In conclusion, allows efficient prediction immune protection various VOCs.

Язык: Английский

Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera

Vaccines, Год журнала: 2024, Номер 12(8), С. 914 - 914

Опубликована: Авг. 13, 2024

Since the initiation of COVID-19 pandemic, there has been a need for development diagnostic methods to determine factors implicated in mounting an immune response against virus. The most promising indicator suggested be neutralizing antibodies (nAbs), which mainly block interaction between Spike protein (S) SARS-CoV-2 and host entry receptor ACE2. In this study, we aimed develop optimize conditions competitive ELISA measure serum titer, using recombinant trimeric modified have six additional proline residues (S(6P)-HexaPro) h-ACE2. results our surrogate Virus Neutralizing Assay (sVNA) were compared commercial sVNT (cPass, Nanjing GenScript Biotech Co., City, China), serially diluted sera from vaccinees, high correlation ID

Язык: Английский